Research recommendation(s) from an individual piece of guidance
- Guidance:
- VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions
- Date issued:
Research recommendations coming out of this guidance
-
What is the impact of using the VivaScope 1500 and 3000 imaging systems in the clinical workflow of melanoma and basal cell carcinoma assessment in secondary care in England, particularly on excision rates, diagnostic accuracy, health related quality of life and associated NHS costs?
-
What proportion of people with melanoma who are referred into secondary care under the 2 week wait rule, have equivocal moles that are excised and have equivocal moles that are monitored?
-
How many confirmatory diagnostic biopsies are carried out before definitive treatment, in people who have a clinical diagnosis of basal cell carcinoma and which different modalities used to treat basal cell carcinoma?
-
What is the clinical effectiveness of using the VivaScope 1500 and 3000 imaging systems to define margins of lentigo maligna and basal cell carcinoma compared with histological margins determined by Mohs surgery?
-
What is the incidence of lentigo maligna diagnosed in England and which different therapies are used to treat lentigo maligna?